Navigation Links
Patient Enrollment in Urgent(R) PC SUmiT Clinical Trial Completed Ahead of Schedule
Date:1/26/2009

kets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder.

We also offer Macroplastique(R) Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure you that the SUmiT clinical trial will produce favorable results, that even if it produces favorable results third-party payers will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses, or that even succeed at all at obtaining a specific "listed" CPT code from the AMA for Urgent PC treatments.

For more information about the Urgent(R) PC Neuromodulation System, please call 866-277-0466 or visit www.uroplasty.com.

For Further Information:

    Uroplasty, Inc.                               EVC Group
    David Ka
'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... , , , WINNIPEG, ... rejected a plan to allow the wholesale reimportation of cheaper ... the drug industry and secure cheaper prescription for Americans. ... for drugs than people in Canada, Australia, the UK, New ...
... Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical ... on December 23, 2009 the Compensation Committee of the Company,s ... to purchase a total of 64,000 shares of common stock ... are intended to be incentive stock options to the extent ...
Cached Medicine Technology:Obama Plan Buckles Under Pharma Lobby; Plan to Import Low-Cost Medicines Derails 2Obama Plan Buckles Under Pharma Lobby; Plan to Import Low-Cost Medicines Derails 3Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635 2Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635 3
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... 2014 Meaningful long-term survival is possible for ... abdomen when treated with cytoreductive surgery with Hyperthermic ... analysis by physicians at Wake Forest Baptist Medical ... reported, single-center experience with cytoreductive surgery and HIPEC, ... analysis of 20 years, worth of patient data ...
(Date:4/17/2014)... adrenaline after they suffer a cardiac arrest outside of ... long-term, according to new research conducted at St. Michael,s ... a cardiac arrest get adrenaline, which has been the ... Dr. Steve Lin, an emergency physician and trauma team ... treatment, long-term survival rates of patients who suffer a ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... ... a David versus Goliath struggle raging in the West, joins the stellar line-up ... York City and in Los Angeles (August 7 - 13). The film will ... the Reel Impact series on Planet Green, a network of Discovery Communications.,Split Estate ...
... , , , ... (Nasdaq: CLRT ), a premier anatomic pathology and molecular ... financial results for the second quarter and six months ended June 30, ... the second quarter of 2009 versus the second quarter of 2008, and ...
... , EAST RUTHERFORD, N.J., Aug. 4 Cambrex Corporation ... 30, 2009. , , Highlights , , ... impact of foreign currency. Reported sales declined by 9.8% for the quarter. , ... in the same quarter last year (see attached table). , ...
... ON, Aug. 4 /PRNewswire-FirstCall/ - Covidien (NYSE: COV ... Nuvo Research Inc. (TSX:NRI), a Canadian drug development company, ... (FDA) has set a new action date under the ... sodium) topical solution 1.5% w/w of November 4, 2009. ...
... , WALTHAM, Mass., Aug. 4 Inverness ... leader in enabling individuals to take charge of their health ... management, today announced that it intends to offer $150 million ... of the notes will be guaranteed by certain of Inverness, ...
... delivery was vaginal or C-section doesn,t matter, study finds ... anesthesia during a Cesarean delivery doesn,t increase the risk ... , "We found that the incidence of learning disabilities ... those who were delivered via C-section but with general ...
Cached Medicine News:Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 2Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 3Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 2Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 3Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 4Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 5Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 6Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 7Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 8Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 9Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 10Health News:Cambrex Reports Second Quarter 2009 Results 2Health News:Cambrex Reports Second Quarter 2009 Results 3Health News:Cambrex Reports Second Quarter 2009 Results 4Health News:Cambrex Reports Second Quarter 2009 Results 5Health News:Cambrex Reports Second Quarter 2009 Results 6Health News:Cambrex Reports Second Quarter 2009 Results 7Health News:Cambrex Reports Second Quarter 2009 Results 8Health News:Cambrex Reports Second Quarter 2009 Results 9Health News:Cambrex Reports Second Quarter 2009 Results 10Health News:Cambrex Reports Second Quarter 2009 Results 11Health News:Cambrex Reports Second Quarter 2009 Results 12Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 2Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 3Health News:Inverness Medical Innovations, Inc. Announces Offering of $150 Million of Senior Notes 2Health News:No Link Found Between Birth Anesthesia and Learning Issues 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: